Targets › HTT
6 programs from 5 companies in 8 trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Neurology; next expected readout Jul 2028.
[Huntingtin]: May play a role in microtubule-mediated transport or vesicle function.; FUNCTION: [Huntingtin, myristoylated N-terminal fragment]: Promotes the formation of autophagic vesicles. (UniProt, P42858)
Open in Phaseline: the race on HTT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Votoplam HTT-lowering antisense oligonucleotide | HTT | Phase 3 | Huntington Disease | Jul 2029 |
| Roche | Tominersen Huntingtin mRNA antisense inhibitor | HTT | Phase 2 | Huntington Disease | – |
| Alnylam Pharmaceuticals | ALN-HTT02 HTT-targeting siRNA (RNAi therapeutic targeting huntingtin mRNA) | HTT | Phase 1 | Huntington's Disease | Jul 2028 |
| UniQure Biopharma | AMT-130 rAAV5-miHTT gene therapy - delivers microRNA targeting mutant huntingtin (HTT) mRNA | HTT | Phase 1 | Huntington Disease; Huntington's Disease | Mar 2029 |
| Roche | SPK-10001 Gene therapy targeting huntingtin gene | HTT | Phase 1 | Huntington Disease | Jan 2035 |
| ExoRNA Bioscience | ER2001 antisense oligonucleotide targeting huntingtin mRNA | HTT | Phase 1 | Huntington Disease | – |
Huntington Disease (6) Huntington's Disease (2)
other (3), small molecule (3)
Roche (2) Alnylam Pharmaceuticals (1) UniQure Biopharma (1) Novartis (1) ExoRNA Bioscience (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.